Remember healthcare is an industry. It’s there to make money for Pharmaceuticals. Big money.

This is an interesting read criticising “corporate health” yet it is relevant to smaller clinic owners, whist anger of medicalising normal life for profit and corporate motives might upset you it is important to also recognise that all clinicians have to market or communicate their services too.

The authors criticise the use of fear-mongering over the creation a positive proactive health message. They also observe that corporate funded information about disease should be replaced by independent information and “de-medicalisation,” based on respect for human dignity is long overdue.

Selling sickness: the pharmaceutical industry and disease mongering

Ray Moynihan, Iona Heath, David HenryBMJ. 2002 Apr 13; 324(7342): 886–891.doi: 10.1136/bmj.324.7342.886

EXTRACT: A lot of money can be made from healthy people who believe they are sick. Pharmaceutical companies sponsor diseases and promote them to prescribers and consumers. Ray Moynihan, Iona Heath, and David Henry give examples of “disease mongering” and suggest how to prevent the growth of this practice

There’s a lot of money to be made from telling healthy people they’re sick. Some forms of medicalising ordinary life may now be better described as disease mongering: widening the boundaries of treatable illness in order to expand markets for those who sell and deliver treatments. Pharmaceutical companies are actively involved in sponsoring the definition of diseases and promoting them to both prescribers and consumers. The social construction of illness is being replaced by the corporate construction of disease.

Whereas some aspects of medicalisation are the subject of ongoing debate, the mechanics of corporate backed disease mongering, and its impact on public consciousness, medical practice, human health, and national budgets, have attracted limited critical scrutiny.

Within many disease categories informal alliances have emerged, comprising drug company staff, doctors, and consumer groups. Ostensibly engaged in raising public awareness about underdiagnosed and undertreated problems, these alliances tend to promote a view of their particular condition as widespread, serious, and treatable. Because these “disease awareness” campaigns are commonly linked to companies’ marketing strategies, they operate to expand markets for new pharmaceutical products. Alternative approaches—emphasising the self limiting or relatively benign natural history of a problem, or the importance of personal coping strategies—are played down or ignored. As the late medical writer Lynn Payer observed, disease mongers “gnaw away at our self-confidence.”

Although some sponsored professionals or consumers may act independently and all concerned may have honourable motives, in many cases the formula is the same: groups and/or campaigns are orchestrated, funded, and facilitated by corporate interests, often via their public relations and marketing infrastructure.

CONTINUE HERE:…/pmc/articles/PMC1122833/…